US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.
first published: Jul 25, 2016 12:00 pm
A collection of the most-viewed Moneycontrol videos.
SOBO to Bandra: Why Only South Mumbai Residents Call Bandra a Downgrade | The Tenant
Live: Nifty registers third straight week of gains, up 2% in November | Closing Bell
Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell
Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell
